Our patients did not receive new tests for molecular abnormalities, such as ASXL1, TP53, and RUNX1, which were recommended by the European LeukemiaNet guidelines in 2017.12 The choice of AML treatment was decided based on patient characteristics and was highly associated with all prognostic factors. This evidence concerns the gene ASXL1 and acute myeloid leukemia.